Education
About Us
Working with TipRanks
Follow Us
Replicel (REPCF)
:REPCF
Total Valuation
RepliCel Life Sciences has a market cap or net worth of $766.80K. The enterprise value is $2.20M.
Market Cap$766.80K
Enterprise Value$2.20M
Share Statistics
RepliCel Life Sciences has 70,003,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,003,020
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
RepliCel Life Sciences’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 192.16%.
Return on Equity (ROE)0.07
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)192.16%
Return on Capital Employed (ROCE)0.90
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover1.23
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio0.6
PS Ratio0.00
PB Ratio-0.19
Price to Fair Value-0.08
Price to FCF-31.44
Price to Operating Cash Flow-26.25
PEG Ratio<0.01
Income Statement
In the last 12 months, RepliCel Life Sciences had revenue of 353.74K and earned -312.00K in profits. Earnings per share was -0.01.
Revenue353.74K
Gross Profit352.26K
Operating Income-1.39M
Pretax Income-312.00K
Net Income-312.00K
EBITDA-1.39M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -235.39K and capital expenditures 0.00, giving a free cash flow of -235.39K billion.
Operating Cash Flow-235.39K
Free Cash Flow-235.39K
Free Cash Flow per Share>-0.01
Dividends & Yields
RepliCel Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta319.33
52-Week Price Change-75.00%
50-Day Moving Average<0.01
200-Day Moving Average―
Relative Strength Index (RSI)0.00
Average Volume (3m)0.00
Important Dates
RepliCel Life Sciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
RepliCel Life Sciences as a current ratio of 0.09, with Debt / Equity ratio of -24.98%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap2.47
Net Debt to EBITDA-0.59
Interest Coverage Ratio-9.30
Taxes
In the past 12 months, RepliCel Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
RepliCel Life Sciences EV to EBITDA ratio is -0.84, with an EV/FCF ratio of -0.83.
EV to Sales3.30
EV to EBITDA-0.84
EV to Free Cash Flow-0.83
EV to Operating Cash Flow-0.83
Balance Sheet
RepliCel Life Sciences has $148.95K in cash and marketable securities with C$1.24M in debt, giving a net cash position of $1.09M billion.
Cash & Marketable Securities$148.95K
Total DebtC$1.24M
Net Cash$1.09M
Net Cash Per Share$0.02
Tangible Book Value Per Share-$0.08
Margins
Gross margin is 99.85%, with operating margin of -391.89%, and net profit margin of -88.13%.
Gross Margin99.85%
Operating Margin-391.89%
Pretax Margin-88.13%
Net Profit Margin-88.13%
EBITDA Margin-391.47%
EBIT Margin-45.98%
Analyst Forecast
The average price target for RepliCel Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―